Total Payments
$1,957
2024 Payments
$569.93
Companies
31
Transactions
99
Medicare Patients
3,189
Medicare Billing
$434,692
Payment Breakdown by Category
Food & Beverage$1,655 (84.5%)
Education$302.78 (15.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,655 | 81 | 84.5% |
| Education | $302.78 | 18 | 15.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $286.24 | 16 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $196.11 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $151.60 | 4 | $0 (2023) |
| GENZYME CORPORATION | $148.89 | 7 | $0 (2024) |
| Merck Sharp & Dohme LLC | $132.73 | 8 | $0 (2023) |
| Celgene Corporation | $108.12 | 6 | $0 (2024) |
| Gilead Sciences, Inc. | $87.37 | 5 | $0 (2024) |
| Genentech USA, Inc. | $82.13 | 4 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $69.08 | 3 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $67.00 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $569.93 | 29 | PFIZER INC. ($194.48) |
| 2023 | $684.04 | 34 | Celgene Corporation ($93.58) |
| 2022 | $111.20 | 6 | PFIZER INC. ($26.27) |
| 2021 | $35.85 | 2 | Myovant Sciences Inc. ($23.93) |
| 2020 | $159.95 | 5 | Janssen Biotech, Inc. ($118.07) |
| 2019 | $218.68 | 13 | Novartis Pharmaceuticals Corporation ($56.44) |
| 2018 | $146.21 | 8 | Pharmacyclics LLC, An AbbVie Company ($40.59) |
| 2017 | $31.55 | 2 | Novartis Pharmaceuticals Corporation ($16.44) |
All Payment Transactions
99 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.49 | General |
| 11/20/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $14.17 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Oncology | ||||||
| 11/11/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: HORMONE THERAPY | ||||||
| 11/04/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 10/07/2024 | Genentech USA, Inc. | Lunsumio (Biological), Polivy | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: BioOncology | ||||||
| 09/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $33.48 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.54 | General |
| Category: Hematology | ||||||
| 08/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.47 | General |
| Category: Oncology | ||||||
| 08/05/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.43 | General |
| Category: Hematology/Oncology | ||||||
| 05/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.91 | General |
| 03/27/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $39.94 | General |
| Category: Oncology | ||||||
| 03/14/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.20 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | PFIZER INC. | TUKYSA (Drug) | Education | In-kind items and services | $16.01 | General |
| Category: Oncology | ||||||
| 03/14/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.13 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.20 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2024 | PFIZER INC. | TUKYSA (Drug) | Education | In-kind items and services | $16.01 | General |
| Category: Oncology | ||||||
| 03/13/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $9.66 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Oncology | ||||||
| 02/28/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.94 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 784 | 1,736 | $290,936 | $107,589 |
| 2022 | 5 | 752 | 1,751 | $268,027 | $103,416 |
| 2021 | 7 | 778 | 1,838 | $248,063 | $113,449 |
| 2020 | 8 | 875 | 2,020 | $275,369 | $110,237 |
Total Patients
3,189
Total Services
7,345
Medicare Billing
$434,692
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 223 | 612 | $116,628 | $41,854 | 35.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 89 | 433 | $62,480 | $25,909 | 41.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 314 | 519 | $66,936 | $22,947 | 34.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 79 | 79 | $20,518 | $7,802 | 38.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 60 | 70 | $17,936 | $6,741 | 37.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 23 | $6,438 | $2,337 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 210 | 610 | $106,040 | $41,270 | 38.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 85 | 470 | $64,500 | $25,357 | 39.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 319 | 529 | $60,462 | $23,052 | 38.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 81 | 81 | $20,881 | $7,534 | 36.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 57 | 61 | $16,144 | $6,203 | 38.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 219 | 676 | $102,752 | $47,279 | 46.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 101 | 466 | $55,920 | $25,890 | 46.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 311 | 546 | $54,054 | $25,424 | 47.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 61 | 63 | $14,175 | $6,172 | 43.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 58 | 58 | $14,558 | $5,961 | 40.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $4,564 | $1,960 | 43.0% |
| 38221 | Biopsy of bone marrow | Facility | 2021 | 14 | 15 | $2,040 | $762.84 | 37.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 276 | 787 | $119,624 | $43,628 | 36.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 104 | 536 | $64,320 | $30,518 | 47.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 317 | 504 | $49,896 | $18,138 | 36.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 61 | 67 | $15,075 | $7,252 | 48.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 63 | 63 | $15,813 | $6,099 | 38.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 17 | 17 | $5,525 | $2,617 | 47.4% |
| 38221 | Bone marrow biopsy | Facility | 2020 | 24 | 27 | $3,672 | $1,397 | 38.1% |
About Dr. Bashar Alasad, M.D
Dr. Bashar Alasad, M.D is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215988803.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bashar Alasad, M.D has received a total of $1,957 in payments from pharmaceutical and medical device companies, with $569.93 received in 2024. These payments were reported across 99 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($1,655).
As a Medicare-enrolled provider, Alasad has provided services to 3,189 Medicare beneficiaries, totaling 7,345 services with total Medicare billing of $434,692. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 05/16/2006
- Last Updated 06/27/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1215988803
Products in Payments
- IBRANCE (Drug) $164.08
- DARZALEX (Biological) $142.11
- KEYTRUDA (Biological) $132.73
- XTANDI (Drug) $105.25
- KISQALI (Drug) $102.67
- ORGOVYX (Drug) $93.01
- REBLOZYL (Biological) $89.56
- SARCLISA (Biological) $76.69
- TUKYSA (Drug) $52.20
- LIBTAYO (Biological) $51.08
- OPDIVO (Biological) $49.68
- Padcev (Drug) $44.55
- Imbruvica (Drug) $40.59
- Venclexta (Drug) $37.76
- JEVTANA (Drug) $37.45
- JAKAFI (Drug) $37.14
- Lenvima (Drug) $35.91
- Lunsumio (Biological) $35.37
- ALIMTA (Drug) $34.76
- ELITEK (Drug) $34.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Hematology & Oncology $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Hematology & Oncology $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Hematology & Oncology $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Hematology & Oncology $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791
Hematology & Oncology $5,791